Omicron sublineage BQ.1.1 resistance to monoclonal antibodies.

Competing Interests: AK, IN, and MH do contract research (testing of vaccinee sera for neutralising activity against SARS-CoV-2) for Valneva, unrelated to this Correspondence. SP does contract research (testing of vaccinee sera for neutralising activity against SARS-CoV-2) for Valneva and served as advisor for BioNTech, unrelated to Correspondence, and acknowledges funding by the Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung [BMBF]; 01KI2006D, 01KI20328A, and 01KX2021), the EU project UNDINE (grant agreement number 101057100), the Ministry for Science and Culture of Lower Saxony (14–76103–184, MWK HZI COVID-19), and the German Research Foundation (DFG; PO 716/11–1 and PO 716/14–1). H-MJ received funding from BMBF (01KI2043 and NaFoUniMedCovid19-COVIM: 01KX2021), the Bavarian State Ministry for Science and the Arts and DFG through the research training groups RTG1660 and TRR130, the Bayerische Forschungsstiftung (Project CORAd), and the Kastner Foundation. All other authors declare no competing interests.